Tariqul Haque Tuhin
Research Subjects
Tariqul Haque Tuhin has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Devin L. Wakefield
Amgen, South San Francisco, CA, USA
2 shared publications Manuel Ponce
Pharmacokinetics & Drug Metabolism, Amgen Research, 1 Amgen Center Drive, Thousand Oaks, California 91320, United States
2 shared publicationsMarcus Soto
Pharmacokinetics & Drug Metabolism, Amgen Research, 1 Amgen Center Drive, Thousand Oaks, California 91320, United States
2 shared publicationsAbdulmalek Balgoname
Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, California 95211, United States
1 shared publicationAchala Punchi Hewage
Pharmacokinetics and Drug Metabolism, Amgen Research, 750 Gateway Blvd, Suite 100, South San Francisco, California 94080, United States
1 shared publicationAditya Jagarapu
Pharmacokinetics and Drug Metabolism, Amgen Research, 750 Gateway Blvd, Suite 100, South San Francisco, CA 94080
1 shared publication
Latest Publications
- 16 January 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (2) , 859-882
Nonspecific Cellular Interactions Are a Key Determinant in the Disposition of Fc-Fused Proteins
As the diversity of therapeutic protein structures continues to evolve, it is essential to understand the mechanisms that determine their pharmacokinetic properties. The current work was initiated to establish the physicochemical attributes and cellular processes most crucial for the target-independent disposition of proteins possessing a fragment crystallizable (Fc) region. We systematically redesigned the surface properties of five de novo-generated protein scaffolds lacking any known binding partner in mice to produce a total of 35 Fc-fused proteins exhibiting a diverse set of physicochemical characteristics. Pharmacokinetic studies in wild-type mice revealed a profound spread in elimination rates and extensive tissue accumulation that was most strongly associated with charge descriptors. A suite of in vitro studies demonstrated that these in vivo observations significantly correlated to cellular nonspecificity wherein positive surface charge caused higher nonspecific adsorptive endocytosis, diminished recycling efficiency by the neonatal Fc receptor, and net cellular accumulation. Combined, our results provide a detailed explanation for how the disposition of Fc-fused proteins is impacted by charge, which will aid protein engineering efforts aimed at optimizing pharmacokinetic features.
- 16 January 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (2) , 859-882
Nonspecific Cellular Interactions Are a Key Determinant in the Disposition of Fc-Fused Proteins
As the diversity of therapeutic protein structures continues to evolve, it is essential to understand the mechanisms that determine their pharmacokinetic properties. The current work was initiated to establish the physicochemical attributes and cellular processes most crucial for the target-independent disposition of proteins possessing a fragment crystallizable (Fc) region. We systematically redesigned the surface properties of five de novo-generated protein scaffolds lacking any known binding partner in mice to produce a total of 35 Fc-fused proteins exhibiting a diverse set of physicochemical characteristics. Pharmacokinetic studies in wild-type mice revealed a profound spread in elimination rates and extensive tissue accumulation that was most strongly associated with charge descriptors. A suite of in vitro studies demonstrated that these in vivo observations significantly correlated to cellular nonspecificity wherein positive surface charge caused higher nonspecific adsorptive endocytosis, diminished recycling efficiency by the neonatal Fc receptor, and net cellular accumulation. Combined, our results provide a detailed explanation for how the disposition of Fc-fused proteins is impacted by charge, which will aid protein engineering efforts aimed at optimizing pharmacokinetic features.
- Open Access
- 19 June 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (9) , 2879-2894
Cellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies
- 19 June 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (9) , 2879-2894
Open AccessCellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies
- 3 November 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (22) , 15473-15486
Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand
This work describes the enhancement of a novel antitumor therapeutic platform that combines advantages from small-molecule drug conjugates (SMDCs) and antibody drug conjugates (ADCs). Valine-citrulline (VCit) dipeptide linkers are commonly used cathepsin B cleavable linkers for ADCs. However, the instability of these linkers in mouse serum makes translating efficacy data from mouse to human more challenging. Replacing the VCit linker with glutamic acid-valine-citrulline (EVCit) has been reported to enhance the stability of ADCs in mouse serum. However, the effect of EVCit linker on the stability of SMDCs has not been reported. Here, we report that incorporating the EVCit linker in prostate-specific membrane antigen-targeting SMDCs, equipped with the transthyretin ligand AG10, resulted in conjugates with lower toxicity, an extended half-life, and superior therapeutic efficacy to docetaxel in a xenograft mouse model of prostate cancer. This should make SMDCs' preclinical toxicity and efficacy data from mice more reliable for predicting human results.
- 3 November 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (22) , 15473-15486
Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand
This work describes the enhancement of a novel antitumor therapeutic platform that combines advantages from small-molecule drug conjugates (SMDCs) and antibody drug conjugates (ADCs). Valine-citrulline (VCit) dipeptide linkers are commonly used cathepsin B cleavable linkers for ADCs. However, the instability of these linkers in mouse serum makes translating efficacy data from mouse to human more challenging. Replacing the VCit linker with glutamic acid-valine-citrulline (EVCit) has been reported to enhance the stability of ADCs in mouse serum. However, the effect of EVCit linker on the stability of SMDCs has not been reported. Here, we report that incorporating the EVCit linker in prostate-specific membrane antigen-targeting SMDCs, equipped with the transthyretin ligand AG10, resulted in conjugates with lower toxicity, an extended half-life, and superior therapeutic efficacy to docetaxel in a xenograft mouse model of prostate cancer. This should make SMDCs' preclinical toxicity and efficacy data from mice more reliable for predicting human results.